Add to bookmarks
Neuromuscular Blockade (NMB) Monitoring

PART 1 - THE BASICS: Myths and Facts: Why Current Practice Fails


  • Image
    Dr. Glen Murphy
    Dr. Glenn Murphy

Welcome to this webinar series presented by the Association of Anaesthetists of Great Britain and Ireland on Neuromuscular Blockade (NMB) Monitoring: Enhancing Clinical Practice. This webinar was sponsored by GE Healthcare.

In this first part, Dr. Glenn Murphy focuses on myths and facts related to neuromuscular management and the reasons why current practices fail.

"Neostigmine DOES NOT produce reliable and rapid reversal. Quantitative monitoring should be used to assess for recovery because reversal times are slow and highly variable with this agent"

Discover the benefits of membership

This webinar was hosted by the Association of Anaesthetists of Great Britain and Ireland.  If you are an Anaesthetist (or a related discipline), you are not a member, enjoyed the webinar and would wish to benefit from more great CPD opportunities, and a large range of great member benefits, please do consider joining the Association. 

Association of Anaesthesiologists logo

Featured Speaker

Dr. Glen Murphy

Dr. Glenn Murphy

Dr Murphy is a researcher with a long history of interest in topics related to neuromuscular blockade. His areas of interest include the incidence of postoperative residual neuromuscular blockade, complications associated with residual neuromuscular blockade, and the impact of neuromuscular monitoring on patient outcomes. 

  • Neurology
  • NMT
  • Intensive care
  • Perioperative care